CLINICAL_TRIALS ClinicalTrials.gov record update

A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05944237
Title field or adapter rule: {'original_value': 'A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:24.415780+00:00
Published At: 2026-10-01T00:00:00+00:00
Record Updated At: 2026-10-01
Source Retrieved At: 2026-10-31T22:17:54.613222+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Neoplasms", "Prostatic Neoplasms, Castration-Resistant", "Stomach Neoplasms", "Esophageal Neoplasms", "Head and Neck Neoplasms", "Colorectal Neoplasms", "Pancreatic Neoplasms", "Lung Neoplasms", "Urinary Bladder Neoplasms", "Mesothelioma, Malignant", "Uterine Cervical Neoplasms", "Kidney Neoplasms", "Sarcoma", "Pheochromocytomas"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-01", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05944237"
protocolSection.identificationModule.officialTitle: "A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Phase 1 Part A HTL0039732 (Dose Escalation Monotherapy)', 'Phase 1 Part B HTL0039732 and Atezolizumab (Dose Escalation Combination)'], 'description': 'HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.', 'name': 'HTL0039732 Capsules', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Phase 2a HTL0039732 and Atezolizumab (Dose Expansion Combination)'], 'description': 'HTL0039732 Capsules or HTL0039732 tablets will be administered orally on a QD schedule to participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Participants will also receive 1200 mg atezolizumab as an IV infusion on Day 1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.', 'name': 'HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.